Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.45 |
| ▸ | EGFR | P00533 | 7/20 | 0.45 |
| ▸ | LCK | P06239 | 7/20 | 0.45 |
| ▸ | ITK | Q08881 | 6/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544659 | 0.81 | BTK (0.55) | BTKEGFRLCKITK | |
| SCHEMBL19544647 | 0.81 | BTK (0.55) | BTKEGFRLCKITK | |
| SCHEMBL19544718 | 0.81 | BTK (0.55) | BTKEGFRLCKITK | |
| SCHEMBL15472753 | 0.80 | BTK (0.59) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19544568 | 0.79 | BTK (0.59) | BTKEGFRLCK | |
| SCHEMBL19544611 | 0.79 | BTK (0.59) | BTKEGFRLCK | |
| SCHEMBL19544728 | 0.79 | BTK (0.54) | BTKEGFRLCKITK | |
| SCHEMBL19544882 | 0.77 | BTK (0.41) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19544559 | 0.76 | KMT2A (0.43) | BTKEGFRKMT2A | |
| SCHEMBL19544717 | 0.76 | BTK (0.47) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | BTK 1/4885EGFR 596/4885LCK 4/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | BTK 1/4885EGFR 596/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.